

Hindawi Publishing Corporation
Mediators of Inflammation
Volume 2016, Article ID 5678046, 10 pages
<http://dx.doi.org/10.1155/2016/5678046>

Research Article

TLR Signalling Pathways Diverge in Their Ability to Induce PGE₂

Valentina Salvi,¹ Xenia Vaira,¹ Veronica Gianello,¹ William Vermi,¹ Mattia Bugatti,¹ Silvano Sozzani,^{1,2} and Daniela Bosisio¹

¹Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy

²Humanitas Clinical and Research Center, 20089 Rozzano, Italy

Correspondence should be addressed to Daniela Bosisio; daniela.bosisio@unibs.it

Received 11 May 2016; Accepted 17 July 2016

Academic Editor: Marja Ojaniemi

Copyright © 2016 Valentina Salvi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PGE₂ is a lipid mediator abundantly produced in inflamed tissues that exerts relevant immunoregulatory functions. Dendritic cells (DCs) are key players in the onset and shaping of the inflammatory and immune responses and, as such, are well known PGE₂ targets. By contrast, the precise role of human DCs in the production of PGE₂ is poorly characterized. Here, we asked whether different ligands of Toll-like receptors (TLRs), a relevant family of pathogen-sensing receptors, could induce PGE₂ in human DCs. The only active ligands were LPS (TLR4 ligand) and R848 (TLR7-8 ligand) although all TLRs, but TLR9, were expressed and functional. While investigating the molecular mechanisms hindering the release of PGE₂, our experiments highlighted so far oversight differences in TLR signalling pathways in terms of MAPK and NF- κ B activation. In addition, we identified that the PGE₂-limiting checkpoint downstream TLR3, TLR5, and TLR7 was a defect in COX2 induction, while TLR1/2 and TLR2/6 failed to mobilize arachidonic acid, the substrate for the COX2 enzyme. Finally, we demonstrated the *in vivo* expression of PGE₂ by myeloid CD11c⁺ cells, documenting a role for DCs in the production of PGE₂ in human inflamed tissues.

1. Introduction

PGE₂ is the predominant eicosanoid produced in inflamed tissues and by growing tumors, with a major contribution by infiltrating immune cells [1, 2]. Because PGE₂ promotes vasodilatation and accumulation of proinflammatory cells, it is generally recognized as a mediator of active inflammation. However, by suppressing the production of some proinflammatory cytokines, PGE₂ also limits nonspecific inflammation and fosters the immune suppression associated with chronic inflammation and cancer [1, 2]. Despite the fact that PGE₂ targeting is easily done by common and effective pharmaceutical agents (i.e., steroids and nonsteroid anti-inflammatory drugs), an accurate understanding of PGE₂ regulation and mechanisms of action is crucial to fully deploy the therapeutic potential of these drugs.

The inflammatory synthesis of PGE₂ is regulated by three classes of enzymes: cytosolic phospholipase A₂ (cPLA₂)

family members that mobilize arachidonic acid (AA) from cellular membranes, cyclooxygenases (COX1 and COX2) that convert AA into PGH₂, and specific synthases accounting for the final conversion of PGE₂ [2]. While COX1 is housekeeping gene governing homeostatic PGE₂ production, COX2 is potently induced by proinflammatory stimuli [3]. In inflammation, the rate of PGE₂ production largely depends on the expression and activity of COX2, although it can be affected by other factors such as local availability of AA [2].

Dendritic cells (DCs) are professional antigen presenting cells responsible for the activation of the adaptive immune response [4] and also play a crucial role in the regulation of inflammation [5, 6]. For doing this, DCs are equipped with the vastest repertoire of pathogen-sensing receptor (pattern recognition receptors, PRR) such as NOD-like receptors, C-type lectin receptors, and Toll-like receptors (TLRs) [7–10].

Human TLRs are a family of type I transmembrane proteins [11]. Upon microbial recognition, TLRs recruit a specific set of adaptor molecules, such as MyD88 and TRIF, to initiate downstream signal transduction pathways. MyD88 is used by all TLRs except TLR3 and activates the transcription factor NF- κ B and mitogen-activated protein kinases (MAPK) to induce inflammatory cytokines. By contrast, TRIF is used by TLR3 (and TLR4) and induces the secretion of type I interferons and also some NF- κ B-dependant genes [11, 12]. The TLR signalling cascades have been described using murine cells from knockout animals or immortalized cell lines of tumor origin. As a result, little is known about the pathways and cellular responses activated by TLRs in human primary cells.

Given the importance of PGE₂ in the orchestration of the immune and inflammatory responses, we set out to dissect the molecular mechanisms underlying its release by TLR-specific ligands in human DCs.

2. Materials and Methods

2.1. Cell Preparation and Culture. Buffy coats were obtained through the courtesy of the Centro Trasfusionale, Spedali Civili, Brescia. Monocytes were purified from peripheral blood mononuclear cells (PBMC) by immunomagnetic separation using anti-CD14-conjugated magnetic microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). DCs were differentiated from monocytes cultured for 6 days in tissue culture plates in RPMI 1640 (Gibco, Life Technologies, Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal calf serum (FCS, Lonza Group, Switzerland), 2 mM L-glutamine, antibiotics (Gibco) (complete RPMI medium), 50 ng/mL GM-CSF, and 20 ng/mL IL-4 (ProSpec Technogene, Israel) as previously described [13]. Myeloid DCs (mDCs) were isolated using the CD1c (BDCA-1)⁺ Dendritic Cell Isolation Kit (Miltenyi Biotec).

2.2. Reagents. DCs or mDCs (2×10^6 cells/mL) were stimulated with the following TLR ligands: 100 ng/mL PAM₃CSK₄, ligand for TLR1/2; 100 ng/mL FSL-1, ligand for TLR2/6; 25 μ g/mL Poly I:C, ligand for TLR3; 100 ng/mL Flagellin, ligand for TLR5 (*Bacillus subtilis*); 5 μ g/mL Imiquimod, ligand for TLR7; 5 μ g/mL R848, ligand for TLR7 and TLR8; 6 μ g/mL CpG ODN 2216, ligand for TLR9 (all from Invivogen, San Diego, California, USA); 100 ng/mL LPS, ligand for TLR4 (*Escherichia coli* 055:B5; Sigma-Aldrich, St. Louis, MO); and heat-killed *Escherichia coli* (specific for TLR4; 1:10 mDC/bacteria ratio, Invivogen). TLR ligand concentrations used in the present paper were determined as optimal for DCs stimulation by preliminary experiments and previously published work by this group [13]. Where indicated, 10 μ M arachidonic acid was added. U0126 (a MEK1/2 inhibitor), PD98059 (an ERK1/2 inhibitor), SB203580 (a p38 MAPK inhibitor), JNK Inhibitor II (a JNK inhibitor), and BAY11-7082 (a NF- κ B inhibitor) were from Calbiochem (San Diego, CA).

2.3. PGE₂ and CXCL8 Determination. DCs were incubated for 24 h with the indicated treatments. Cell-free supernatants were harvested and PGE₂ production was measured by EIA (Cayman Chemical) kit. Secreted CXCL8 was measured by ELISA assay according to the manufacturer instructions (R&D Systems, Minneapolis, MN, USA).

2.4. Real-Time PCR. RNA was extracted in TRIzol, according to the manufacturer's instructions. After RNA purification, samples were treated with DNase to remove contaminating genomic DNA (DNaseI amplification grade). Reverse transcription was performed using random hexamers and Superscript II RT. All reagents were from Invitrogen. The iQTM SYBR Green Supermix (Bio-Rad Laboratories Inc., Hercules, CA, USA) for quantitative real-time PCR was used according to manufacturer's instructions. Reactions were run in triplicate on an iCyclerTM (Bio-Rad Laboratories Inc.) and the generated products analysed by the iCycler iQ Optical System Software (Version 3.0a, Bio-Rad Laboratories Inc.). Gene specific primers were as follows: hHPRT (forward: 5'-CCAGTAACAGGGGACATAAAA-3', reverse: 5'-CAC-AATCAAGACATTCTTTCCAGT-3'); hTLR1 (forward: 5'-CCTAGCAGTTATCACAAGCTCAAA-3', reverse: 5'-TC-TTTTCCTTGGGCCATTC-3'); hTLR2 (forward: 5'-CG-TTCTCTCAGGTGACTGCTC-3', reverse: 5'-CCTTTGGA-TCCTGCTTGC-3'); hTLR3 (forward: 5'-AGTTGTCATCG-AATCAAATTAAGAG-3', reverse: 5'-AATCTTCCAAT-TGCGTGAAAA-3'); hTLR4 (forward: 5'-CTCCCCTG-TACCCTTCTCACT-3', reverse: 5'-CTCCCCTGCCTTGAA-TACCTTC-3'); hTLR5 (forward: 5'-GACACAATCTCGGC-TGACTG-3', reverse: 5'-GCCAGGAACATGAACATCAA-3'); hTLR6 (forward: 5'-TGAAACAGTCTCTTTTGTAGT-AAATGC-3', reverse: 5'-TCCATTTGGGAAAGCAGAGT-3'); hTLR7 (forward: 5'-TTAACCAATTGCTTCCGTGTC-3', reverse: 5'-GGTGCCACACTCAATCTG-3'); hTLR8 (forward: 5'-TGTGGTTGTTTTCTGGATTCAA-3', reverse: 5'-GCTCGCATGGCTTACATGA-3'); hTLR9 (forward: 5'-TGTGAAGCATCCTTCCCTGT-3', reverse: 5'-GAGAG-ACAGCGGGTGCAG-3'). Gene expression was normalized based on HPRT mRNA content.

2.5. SDS-PAGE and Western Blot. Following the designated treatments, DCs were washed twice with PBS and lysed in LI buffer (50 mM Tris-HCl, pH 8.0; 2 mM EDTA; 0.1% NP-40 and 10% glycerol) with inhibitors to separate cytoplasmic proteins. Nuclear pellets were washed twice with LI buffer with inhibitors and then lysed in NP-40 Lysis buffer (50 mM Tris-HCl, pH 8.0; 250 mM NaCl; 1 mM EDTA; 0.1% NP-40; and 10% glycerol) with inhibitors. Total cell extracts were obtained with NP-40 Lysis buffer. Equal amounts of cytoplasmic, nuclear, or total extracts were analysed through 8–12% SDS-PAGE followed by Western blotting with antibodies against COX2 (mouse monoclonal, Cat. 160112, Cayman Chemical), phospho-ERK1/2 (rabbit polyclonal, Cat. 9101, Cell Signalling Technologies, Massachusetts, USA), phospho-p38 (rabbit polyclonal, Cat. 9211, Cell Signalling), phospho-cPLA₂ (rabbit polyclonal, Cat. 2831, Cell Signalling), phospho-MSK1 (rabbit polyclonal, Cat. 9595, Cell Signalling), NF- κ B p65 (rabbit

polyclonal, C-20 Cat. sc-372, Santa Cruz Biotechnology), β -actin (mouse monoclonal, C-4 Cat. sc-44478, Santa Cruz Biotechnology), and Lamin B (goat polyclonal, C-20 Cat. sc-6216, Santa Cruz Biotechnology). Protein bands were detected with SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, USA). Densitometric analysis was performed using ImageJ (version 1.48) software package from National Institutes of Health. Immunoblots were scanned as JPEG images and the areas under the curves were measured for each band and quantified. Data were normalized based on β -actin or Lamin B content.

2.6. Release of [14 C] AA. DCs (6×10^6 /mL, in RPMI 1640, 10% FCS) were labelled in Petriperm dishes with $0.125 \mu\text{Ci}/\text{mL}$ [14 C] AA (Amersham, Buckingham, UK) overnight. At the end of the incubation, cells were washed twice and resuspended in RPMI 1640 supplemented with 0.2% fatty acid free bovine serum albumin (Sigma). DCs were stimulated for 3 h and the reaction was terminated by the addition of 2 mL of chloroform/methanol/formic acid (1:2:0.2, v/v/v, all from Sigma-Aldrich) followed by agitation. Then, 1 mL of water and 2 mL chloroform were added. Chromatographic separation of lipids was performed by evaporating the organic phase under a stream of nitrogen, redissolving the residue in chloroform, and loading the extract on silica gel G plates (Merck, Darmstadt, Germany). Fatty acids were separated by thin layer chromatography using hexane/ethyl ether/formic acid (15:10:1, v/v/v, all from Sigma-Aldrich) as a solvent system for 30 min. AA position on TLC plates was determined as comigration with commercially available standard after exposure to iodine vapors. Autoradiography of TLC plates was performed using a phosphoimaging system (FLA 2000, Fuji). The results are expressed as the percentage of radioactivity in the arachidonic acid band on the total radioactivity recovered from each lane.

2.7. Immunohistochemistry. Formalin-fixed paraffin-embedded human tissues were retrieved from the archive of the Department of Pathology (Spedali Civili di Brescia, Brescia, Italy). Anti-PGE₂ (rabbit polyclonal, 1:700 overnight, Biorbyt) was revealed using DakoEnvision + System-HRP Labelled Polymer Anti-Rabbit and DAB after antigen retrieval (thermostatic bath, TRIS-EDTA buffer, pH 9.0). Characterization of PGE₂ positive cells was performed by double immunohistochemistry using CD11c (mouse, clone 5D11, 1:50, Leica Microsystems) and visualized using Mach 4 MR-AP (Biocare Medical, CA), followed by Ferangi Blue (Biocare Medical) as chromogen. Immunostained sections were photographed using the DP-70 Olympus digital camera mounted on the Olympus BX60 microscope.

2.8. Statistical Analysis. Statistical significance between the experimental groups was determined using one-way ANOVA with Dunnett's *post hoc* test (GraphPad Prism version 4.00 for Windows, GraphPad Software).

3. Results and Discussion

3.1. The Stimulation of TLR4 and TLR7-8 Induces PGE₂ in Human DCs. Human DCs were stimulated with TLR-specific ligands and analysed for the release of PGE₂. Figure 1(a) shows that, in addition to LPS (TLR4 ligand), only R848 (TLR7 and TLR8 ligand, from now on TLR7-8) could stimulate the secretion of PGE₂. The ligands for TLR1/2 (PAM₃CSK₄), TLR2/6 (FSL-1), TLR3 (Poly I:C), TLR5 (Flagellin), TLR7 (Imiquimod), and TLR9 (CpG) were by contrast ineffective. Thus, we asked whether these receptors were expressed and functional in DCs. Figure 1(b) shows that DCs express all TLR mRNAs, exception made for TLR9. While the absence of TLR9 in myeloid DCs is generally recognized, the expression of TLR7 is controversial [14–16]. However, since TLR1–8 ligands activated DCs to produce CXCL8 (Figure 1(c)), we concluded that these receptors were indeed expressed and functional in our experimental setting. CpG was excluded from further analysis because of the lack of its cognate receptor.

Previous works have compared TLR ligands for their capability to induce differential cytokine production by human DCs [17–22]. To our knowledge, our study is the first to investigate eicosanoid production induced by different TLRs and to highlight so far oversight differential ability of TLR ligands to induce the release of PGE₂ in human DCs.

3.2. MAPKs and NF- κ B Are Key Downstream Signalling Molecules for PGE₂ Production. LPS, a ligand inducing robust PGE₂ secretion over a vast range of concentrations (Figure 2(a)), was used to further investigate the signalling pathways responsible for PGE₂ production in DCs. Since in other experimental settings the regulation of PGE₂ involves the activation of MAPKs and NF- κ B [3, 23, 24], DCs were stimulated in the presence of specific MAPK inhibitors such as U0126 (inhibitor of MAPK kinase), PD98059 (inhibitor of extracellular-signal-regulated kinase 1/2-ERK1/2), SB203580 (inhibitor of MAPK p38), and, of the NF- κ B inhibitor, BAY11-7082, which all significantly reduced the release of PGE₂ (Figure 2(b)) when used at the lower concentration, without affecting cell viability (not shown). Of note, the same signalling pathways also regulated the induction of COX2, the rate-limiting enzyme for PGE₂ synthesis (Figure 2(c)).

These results confirm that, in human DCs, the release of PGE₂ depends on the activation of the MAPK and NF- κ B pathways.

3.3. TLR Ligands Differentially Activate MAPKs and NF- κ B in Human DCs. In order to clarify the molecular mechanisms hindering the release of PGE₂ by inactive TLR ligands, we analysed how different TLR stimulation impacted the activation of MAPKs and NF- κ B. Figure 3 shows that all ligands induced ERK1/2 phosphorylation, although at different extent. However only LPS, R848, PAM₃CSK₄, and FSL-1 also induced p38 phosphorylation and NF- κ B p65 nuclear translocation, while Poly I:C, Flagellin, and Imiquimod did not. Finally, TLR2 ligands failed to phosphorylate MSK1, a




FIGURE 1: TLR4 and TLR7-8 stimulation induce the secretion of PGE₂ by DCs. ((a) and (c)) DCs at day 6 of culture were stimulated with PAM₃CSK₄ (100 ng/mL), FSL-1 (100 ng/mL), Poly I:C (25 μg/mL), LPS (100 ng/mL), Flagellin (100 ng/mL), Imiquimod (5 μg/mL), R848 (5 μg/mL), and CpG (6 μg/mL). After 24 h, supernatants were collected and the production of PGE₂ (a) and CXCL8 (c) was evaluated by EIA or ELISA, respectively. Results are expressed as mean ± SEM ($n = 4$); * $P < 0.05$ compared with respective controls by one-way ANOVA with Dunnett's *post hoc* test. (b) mRNA from DCs at day 6 of culture was extracted to analyse the expression of TLRs. Data are expressed as mean ± SEM ($n = 3$).

kinase downstream ERK and p38 MAPK that was described to play a role in PGE₂ production [25, 26]. Similar activation patterns were also detected at 15 and 60 minutes after stimulation (not shown).

Such striking differences in the activation of MAPKs and NF-κB are interesting because, according to the literature, all TLR agonists are expected to converge on these pathways to exert their biological effects [27, 28]. Our results underline the importance to confirm and refine previous findings, obtained

in model cell lines and often by transfection, in primary cells expressing TLRs at physiological levels.

Of particular interest was the difference in the activation induced by Imiquimod and R848, both in terms of intracellular signalling and in terms of PGE₂ secretion. TLR7 and TLR8 both recognize ssRNA, are similar in sequence and localization, and, together with TLR9, form an evolutionary related TLR subfamily sharing common signalling pathways responsible for antiviral responses [28].




FIGURE 2: The release of PGE₂ by DCs depends on the activation of the MAPK and NF-κB pathways. (a) DCs were stimulated with increasing concentrations of LPS for 24 h and PGE₂ production was quantified by EIA. Data are expressed as mean ± SEM (n = 3); *P < 0.05 by one-way ANOVA with Dunnett's *post hoc* test. (b) DCs were pretreated for 1 h with the indicated doses of U0126, PD98059, SB203580, or BAY-11-7082 and then stimulated with LPS (100 ng/mL) for 24 h. The production of PGE₂ was evaluated in cell-free supernatants by EIA. Results are expressed as mean ± SEM (n = 3); *P < 0.05 by one-way ANOVA with Dunnett's *post hoc* test. (c) DCs were treated as in (b), using 1 μM of each inhibitor. The expression of COX2 and β-actin was determined by Western blot. One representative fluorogram out of three and its densitometric analysis are shown.

The differences we have observed may thus merely depend on the limited expression of TLR7, which would explain the lower PGE₂ secretion induced by Imiquimod. However, Imiquimod phosphorylated ERK1/2 at levels that were comparable to, if not exceeding, those induced by R848, despite the fact that it failed to activate other signalling molecules. This may unveil a qualitative rather than a quantitative difference between the signalling pathways activated by TLR7 and TLR8, as suggested by other authors [20, 29]. In addition,

we hypothesized that R848, by concomitantly triggering TLR7 and TLR8, may activate a synergy between the two signalling pathways. This issue represent an interesting area of investigation that will be intensively pursued.

3.4. TLR3, TLR5, and TLR7 Stimulation Fail to Induce COX2, While TLR1/2 and TLR2/6 Stimulation Fail to Mobilize AA. We next examined how the TLR-activated signalling




FIGURE 3: TLRs differentially activate the MAPK and NF- κ B pathways. DCs were stimulated with TLR agonists as indicated in Figure 1 for 30 min. After cell lysis, extracts were blotted against phospho-p38, phospho-ERK1/2, and phospho-MSK1. Nuclear extracts were blotted against NF- κ B p65. β -actin and Lamin B represent loading controls for total and nuclear proteins, respectively. The image depicts results obtained in one representative donor out of three.

pathways could differentially affect COX2 activation. Because COX2 activity directly correlates with protein levels [3], Western blot analysis was used to address this issue. Figure 4(a) clearly shows that Poly I:C, Flagellin, and Imiquimod failed to induce COX2 accumulation, which fully explains the lack of PGE₂ secretion and also confirms that NF- κ B activation is critical for COX2 expression [23, 24]. By contrast, PAM₃CSK₄ and FSL-1 were as effective as LPS or R848 in COX2 induction, suggesting that these ligands lack in downstream steps of PGE₂ synthesis.

Thus, we analysed the activation of cPLA₂, the other PGE₂ key-producing enzyme. Within minutes, cPLA₂ is regulated by phosphorylation [30]. We found that only LPS and R848 induced significant cPLA₂ phosphorylation at 30 minutes after stimulation (Figure 4(b)). Based on the observations in Figure 3, it is tempting to speculate that, in our system,

cPLA₂ phosphorylation may depend on MSK1 activation, as previously demonstrated in human fibroblasts stimulated with IL-1 β [25, 26].

Consistent with inefficient cPLA₂ phosphorylation, PAM₃CSK₄ and FSL-1 did not induce AA release as compared to LPS and R848 (Figure 4(c)), suggesting that TLR1/2 and TLR2/6 stimulation may fail to induce PGE₂ secretion because of the unavailability of AA, the substrate for COX2 enzyme. According to this hypothesis, the administration of exogenous AA (Figure 4(d), black bars) restored the production of PGE₂ by PAM₃CSK₄ and FSL-1, but not by Poly I:C, Flagellin, and Imiquimod due to their inability to accumulate COX2.

Altogether, these results identify AA and COX2 accumulation as the PGE₂-limiting checkpoints downstream TLR1/2-2/6 and TLR3-5-7 stimulation, respectively.




FIGURE 4: Lack of AA mobilization blocks the release of PGE₂ upon TLR1/2 and TLR2/6 stimulation. (a) DCs were stimulated with TLR agonists for 24 h. The expression of COX2 and β -actin was determined by Western blot. Fluorogram from one out of 3 representative donors and its densitometric analysis are shown. (b) DCs were stimulated with TLR agonists for 30 min and the phosphorylation of cPLA₂ was determined by immunoblot. One out of 3 representative donors and its densitometric analysis are shown. (c) DCs were labelled with 0.125 $\mu\text{Ci}/\text{mL}$ [¹⁴C] AA overnight and then stimulated with the indicated TLR ligands for 3 h. The results are expressed as the means \pm SEM ($n = 3$) of the percentage of [¹⁴C] AA release on the total radioactivity recovered from each stimulation; * $P < 0.05$ by one-way ANOVA with Dunnett's *post hoc* test. (d) DCs were incubated with TLR ligands in the presence (black bars) or absence (white bars) of 10 μM AA. After 24 h, supernatants were collected and the production of PGE₂ was evaluated by EIA. Results are expressed as mean \pm SEM ($n = 3$); * $P < 0.05$ by one-way ANOVA with Dunnett's *post hoc* test.

3.5. Human DCs Produce PGE₂ In Vivo. Despite the fact that DCs are very well known PGE₂ targets [2], their potential as prostaglandin sources in humans is less investigated and remains under debate. In fact, using *in vitro* differentiated DCs as a model, it was described that human DCs either could [31, 32] or could not produce PGE₂ [33]. In addition, the

strict ligand selectivity we have demonstrated so far raises the question of how primary DCs may respond to real pathogens in terms of PGE₂ production.

To shed light on the possible role of DCs as PGE₂-producing cells *in vivo*, we stimulated primary, circulating mDCs with TLR4 ligands. Figure 5(a) shows that these




FIGURE 5: CD11c⁺ cells produce PGE₂ in human inflamed lymph nodes. (a) Circulating mDCs were stimulated with LPS (100 ng/mL) or heat-killed *E. coli* (1:10 mDC/bacteria ratio). After 24 h, supernatants were collected and the production of PGE₂ was evaluated by EIA. Data are expressed as mean \pm SEM ($n = 3$); * $P < 0.05$ by one-way ANOVA with Dunnett's *post hoc* test. (b) Sections from FFPE reactive lymph nodes were stained as indicated. Cytoplasmic PGE₂ is observed in a fraction of CD11c⁺ cells. Representative double positive cells are indicated by arrow heads. Sections are counterstained with Meyer's haematoxylin. Original magnifications: 400x (scale bar 50 μ m).

cells respond to TLR4 stimulation releasing amounts of PGE₂ that are much higher than those observed for their *in vitro*-derived counterparts. This is in line with previous observations that IL-4 used to generate DCs may hinder the activity of cPLA₂ [33]. Finally, we performed double immunohistochemistry stainings on human inflamed lymph nodes, showing a fraction of CD11c⁺ cells expressing PGE₂ in their cytoplasm (Figure 5(b)).

These results conform that primary DCs can actively secrete PGE₂ in inflammatory conditions *in vivo*.

The net effect of the simultaneous stimulation of different TLRs and also of other classes of innate immune receptors by whole microorganisms remains to be elucidated. However, it is plausible that pathogens expressing molecular patterns activating TLR4 and TLR7-8 may be stronger PGE₂ inducers. Thus, the pathogen-dictated modulation of the release of PGE₂ may represent a novel mechanism through which DCs shape the immune and inflammatory responses.

4. Conclusion

In the present paper, we demonstrate a differential ability of TLR ligands to induce the release of PGE₂ and provide a detailed description of the mechanisms governing TLR-mediated eicosanoid production in human DCs. A schematic representation of our findings is outlined in Figure 6. Briefly, only the stimulation of TLR4 and TLR7-8 could activate ERK1/2, p38, MSK1, and NF- κ B and induce PGE₂. By contrast, the PGE₂-limiting checkpoints downstream TLR1/2-2/6 and TLR3-5-7 stimulation were identified in AA and COX2 accumulation, respectively.

Our results also highlighted so far oversight differences in MAPK and NF- κ B activation by TLR ligands. These divergences may have come to light because, contrary to works performed in transfected cell lines, our system consisted of primary cells expressing a physiologic repertoire of receptors and intracellular adaptor molecules.

Finally, by demonstrating the expression of PGE₂ by CD11c⁺ cells in human inflamed lymph nodes, this study further expands our knowledge on the complex role of DCs in the regulation of immune responses.

Competing Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors' Contributions

Silvano Sozzani and Daniela Bosisio equally contributed to this paper.

Acknowledgments

This work was supported by AIRC (the Italian Association for Cancer Research); Fondazione Berlucci; MIUR (Ministero dell'Istruzione Università e Ricerca) e Fondazione Cariplo. Valentina Salvi was the recipient of a fellowship from FIRC (Fondazione Italiana Ricerca sul Cancro). Veronica Gianello was supported by the IAP (Interuniversity Attraction Poles) 7-40 program.




FIGURE 6: Mechanisms of PGE₂ production by TLR family members. TLR4 triggering induces the transcription of COX2 via NF-κB and MAPK p38 and ERK1/2 as well as cPLA₂ phosphorylation and AA mobilization, presumably via MAPK and/or MSK1, which is in turn converted into PGE₂ by COX2 and released into the medium. Similar mechanisms of action can be envisaged when TLR7 and 8 are concomitantly activated by R848. TLR3, TLR5, and TLR7 fail to activate NF-κB and selected MAPKs, thus hindering the transcription of COX2. By contrast, TLR1/2 and TLR2/6 cause no PGE₂ release because of inefficient cPLA₂ phosphorylation and AA mobilization, which may correlate with their inability to phosphorylate MSK1.

References

- [1] E. Eruslanov, I. Daurkin, J. Ortiz, J. Vieweg, and S. Kusmartsev, "Pivotal advance: tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE₂ catabolism in myeloid cells," *Journal of Leukocyte Biology*, vol. 88, no. 5, pp. 839–848, 2010.
- [2] P. Kalinski, "Regulation of immune responses by prostaglandin E₂," *Journal of Immunology*, vol. 188, no. 1, pp. 21–28, 2012.
- [3] C. D. Funk, "Prostaglandins and leukotrienes: advances in eicosanoid biology," *Science*, vol. 294, no. 5548, pp. 1871–1875, 2001.
- [4] H. Ueno, N. Schmitt, E. Klechevsky et al., "Harnessing human dendritic cell subsets for medicine," *Immunological Reviews*, vol. 234, no. 1, pp. 199–212, 2010.
- [5] S. Sozzani, M. Rusnati, E. Riboldi, S. Mitola, and M. Presta, "Dendritic cell-endothelial cell cross-talk in angiogenesis," *Trends in Immunology*, vol. 28, no. 9, pp. 385–392, 2007.
- [6] M. Merad, P. Sathe, J. Helft, J. Miller, and A. Mortha, "The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting," *Annual Review of Immunology*, vol. 31, pp. 563–604, 2013.
- [7] M. Muzio, D. Bosisio, N. Polentarutti et al., "Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells," *Journal of Immunology*, vol. 164, no. 11, pp. 5998–6004, 2000.
- [8] T.-D. Kanneganti, M. Lamkanfi, and G. Núñez, "Intracellular NOD-like receptors in host defense and disease," *Immunity*, vol. 27, no. 4, pp. 549–559, 2007.

- [9] T. B. H. Geijtenbeek and S. I. Gringhuis, "Signalling through C-type lectin receptors: shaping immune responses," *Nature Reviews Immunology*, vol. 9, no. 7, pp. 465–479, 2009.
- [10] M. Muzio, N. Polntarutti, D. Bosisio, M. K. Prahladan, and A. Mantovani, "Toll like receptor family (TLT) and signalling pathway," *European Cytokine Network*, vol. 11, no. 3, pp. 489–490, 2000.
- [11] T. Kawai and S. Akira, "Toll-like receptors and their crosstalk with other innate receptors in infection and immunity," *Immunity*, vol. 34, no. 5, pp. 637–650, 2011.
- [12] J. Brown, H. Wang, G. N. Hajishengallis, and M. Martin, "TLR-signaling networks: an integration of adaptor molecules, kinases, and cross-talk," *Journal of Dental Research*, vol. 90, no. 4, pp. 417–427, 2011.
- [13] V. Salvi, S. Scutera, S. Rossi et al., "Dual regulation of osteopontin production by TLR stimulation in dendritic cells," *Journal of Leukocyte Biology*, vol. 94, no. 1, pp. 147–158, 2013.
- [14] E. Bourke, D. Bosisio, J. Golay, N. Polntarutti, and A. Mantovani, "The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells," *Blood*, vol. 102, no. 3, pp. 956–963, 2003.
- [15] A. Krug, A. Towarowski, S. Britsch et al., "Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12," *European Journal of Immunology*, vol. 31, no. 10, pp. 3026–3037, 2001.
- [16] D. Jarrossay, G. Napolitani, M. Colonna, F. Sallusto, and A. Lanzavecchia, "Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells," *European Journal of Immunology*, vol. 31, no. 11, pp. 3388–3393, 2001.
- [17] F. Re and J. L. Strominger, "Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells," *The Journal of Biological Chemistry*, vol. 276, no. 40, pp. 37692–37699, 2001.
- [18] D. Werling and T. W. Jungi, "TOLL-like receptors linking innate and adaptive immune response," *Veterinary Immunology and Immunopathology*, vol. 91, no. 1, pp. 1–12, 2003.
- [19] A. M. Lundberg, S. K. Drexler, C. Monaco et al., "Key differences in TLR3/poly I:C signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems," *Blood*, vol. 110, no. 9, pp. 3245–3252, 2007.
- [20] A. Larangé, D. Antonios, M. Pallardy, and S. Kerdine-Römer, "TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation," *Journal of Leukocyte Biology*, vol. 85, no. 4, pp. 673–683, 2009.
- [21] J. Suurmond, A. L. Dorjée, E. F. Knol, T. W. J. Huizinga, and R. E. M. Toes, "Differential TLR-Induced cytokine production by human mast cells is amplified by FcεRI triggering," *Clinical and Experimental Allergy*, vol. 45, no. 4, pp. 788–796, 2015.
- [22] H. Qi, T. L. Denning, and L. Soong, "Differential induction of interleukin-10 and interleukin-12 in dendritic cells by microbial Toll-like receptor activators and skewing of T-cell cytokine profiles," *Infection and Immunity*, vol. 71, no. 6, pp. 3337–3342, 2003.
- [23] S. Nakao, Y. Ogata, E. Shimizu-Sasaki, M. Yamazaki, S. Furuyama, and H. Sugiyama, "Activation of NFκB is necessary for IL-1β-induced cyclooxygenase-2 (COX-2) expression in human gingival fibroblasts," *Molecular and Cellular Biochemistry*, vol. 209, no. 1–2, pp. 113–118, 2000.
- [24] R. Newton, L. M. E. Kuitert, M. Bergmann, I. M. Adcock, and P. J. Barnes, "Evidence for involvement of NF-κB in the transcriptional control of COX-2 gene expression by IL-1β," *Biochemical and Biophysical Research Communications*, vol. 237, no. 1, pp. 28–32, 1997.
- [25] K. F. MacKenzie, M. W. M. Van Den Bosch, S. Naqvi et al., "MSK1 and MSK2 inhibit lipopolysaccharide-induced prostaglandin production via an interleukin-10 feedback loop," *Molecular and Cellular Biology*, vol. 33, no. 7, pp. 1456–1467, 2013.
- [26] J. N. Walters, J. S. Bickford, D. E. Beachy et al., "cPLA₂α gene activation by IL-1β is dependent on an upstream kinase pathway, enzymatic activation and downstream 15-lipoxygenase activity: a positive feedback loop," *Cellular Signalling*, vol. 23, no. 12, pp. 1944–1951, 2011.
- [27] T. Kawai and S. Akira, "Signaling to NF-κB by Toll-like receptors," *Trends in Molecular Medicine*, vol. 13, no. 11, pp. 460–469, 2007.
- [28] T. Kawai and S. Akira, "TLR signaling," *Seminars in Immunology*, vol. 19, no. 1, pp. 24–32, 2007.
- [29] K. B. Gorden, K. S. Gorski, S. J. Gibson et al., "Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8," *Journal of Immunology*, vol. 174, no. 3, pp. 1259–1268, 2005.
- [30] M. A. Gijón and C. C. Leslie, "Regulation of arachidonic acid release and cytosolic phospholipase A2 activation," *Journal of Leukocyte Biology*, vol. 65, no. 3, pp. 330–336, 1999.
- [31] M. Fogel-Petrovic, J. A. Long, D. A. Knight, P. J. Thompson, and J. W. Upham, "Activated human dendritic cells express inducible cyclo-oxygenase and synthesize prostaglandin E2 but not prostaglandin D2," *Immunology and Cell Biology*, vol. 82, no. 1, pp. 47–54, 2004.
- [32] M. Jefford, M. Schnurr, T. Toy et al., "Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli," *Blood*, vol. 102, no. 5, pp. 1753–1763, 2003.
- [33] C. Zelle-Rieser, R. Ramoner, E. Artner-Dworzak, A. Casari, G. Bartsch, and M. Thurnher, "Human monocyte-derived dendritic cells are deficient in prostaglandin E2 production," *FEBS Letters*, vol. 511, no. 1–3, pp. 123–126, 2002.